• Most Popular
  • Most Shared

Alcon ends macular degeneration drug program

LOS ANGELES
Fri Jul 11, 2008 7:06pm EDT

LOS ANGELES (Reuters) - Alcon Inc said on Friday that it has ended development of anecortave acetate as a treatment for lowering the risk of a sight-threatening eye disease known as age-related macular degeneration.

Science  |  Health  |  Stocks  |  Regulatory News  |  Global Markets

Alcon said the decision followed a planned interim analysis of clinical studies.

The company said it continues to study anecortave acetate to reduce intraocular pressure in patients with open-angle glaucoma.

(Reporting by Deena Beasley, editing by Richard Chang)
Science
Health
Stocks
Regulatory News
Global Markets


More from Reuters

Photo

New security restrictions could hurt airlines

NEW YORK (Reuters) - Tighter security measures at U.S. airports following an attempt to blow up a Detroit-bound jet could dampen enthusiasm for air travel, hurting the airline industry just as it seemed poised to recover from a period of bruising losses, some industry experts say.

» More Top News
A Delta Airbus 330 airliner sits on a runway at Detroit Metropolitan Airport in Romulus, Michigan in this video grab made December 25, 2009. Credit: REUTERS/WDIV TV/Handout

The battle in mid-air

The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers.  Full Article 

U.S.
A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
Political Risk in 2010:

Don't say we didn't warn you

With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

Global Markets